Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expectations of Response from Octreotide Therapy in Recurrent Phosphaturic Mesenchymal Tumors - Do They Reflect Reality?

  • Ulas, Arife (Ankara Ataturk Training and Research Hospital) ;
  • Dede, Didem Sener (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research And Training Hospital, Department of Medical Oncology) ;
  • Sendur, Mehmet Ali Nahit (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research And Training Hospital, Department of Medical Oncology) ;
  • Akinci, Muhammed Bulent (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research And Training Hospital, Department of Medical Oncology) ;
  • Yalcin, Bulent (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research And Training Hospital, Department of Medical Oncology)
  • Published : 2015.01.22
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Carpenter TO (2003). Oncogenic osteomalacia - a complex dance of factors. N Engl J Med, 348, 1705-8. https://doi.org/10.1056/NEJMe030037
  2. Clifton-Bligh RJ, Hofman MS, Duncan E (2013). Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab, 98, 687-94. https://doi.org/10.1210/jc.2012-3642
  3. Folpe AL, Fanburg-Smith JC, Billings SD, et al (2004). Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol, 28, 1-30. https://doi.org/10.1097/00000478-200401000-00001
  4. Guo LJ, Tang CW (2014). Somatostatin analogues do not prevent carcinoid crisis. Asian Pac J Cancer Prev, 15, 6679-83 https://doi.org/10.7314/APJCP.2014.15.16.6679
  5. Houang M, Clarkson A, Sioson L, et al (2013). Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol Dec, 44, 2711-8. https://doi.org/10.1016/j.humpath.2013.07.016
  6. Jan de Beur SM, Streeten EA, Civelek AC (2002). Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet, 359, 761-3. https://doi.org/10.1016/S0140-6736(02)07846-7
  7. Jan de Beur SM (2005). Tumor-induced osteomalacia. JAMA, 294, 1260-7 https://doi.org/10.1001/jama.294.10.1260
  8. Jonsson KB, Zahradnik R, Larsson T, et al (2003). Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med, 348, 1656-63. https://doi.org/10.1056/NEJMoa020881
  9. Paglia F, Dionisi S, Minisola S (2002). Octreotide for Tumor- Induced Osteomalacia N Engl J Med, 30, 1748-9
  10. Reubi JC, Waser B, Laissue JA, Gebbers JO (1996). Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res, 56, 1922-31
  11. Rodrigues NR, Calich AL, Etchebehere M, et al (2014). Whole- Body 99mTc-Octreotide Scintigraphy with SPECT/CT to Detect Occult Tumor Inducing Paraneoplastic Osteomalacia. Clin Nuc Med, 22.
  12. Seufert J, Ebert K, Muller J et al (2001). Octreotide for tumorinduced osteomalacia. N Engl J Med, 345,1883 https://doi.org/10.1056/NEJMoa010839
  13. Weider N, Santa Cruz D (1987). Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer, 59, 1442-54. https://doi.org/10.1002/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q
  14. Wynick D, Anderson JV, Williams SJ, et (1989). Resistance to metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol, 30, 385-8. https://doi.org/10.1111/j.1365-2265.1989.tb00436.x